Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Investigators examine the exposure and overdose rates of a popular anxiety treatment for adolescents between 2000-2015.
Diane Calello, MD
A team, led by Diane Calello, MD, executive and medical director of the New Jersey Poison Control Center at Rutgers New Jersey Medical School's Department of Emergency Medicine, have identified national trends for pediatric benzodiazepine exposures between 2000-2015 after gathering data from 296,838 pediatric patients.
In the retrospective analysis, investigators procured data of benzodiazepine exposures in adolescences under the age of 18 who reported to participating US poison centers. The exposure data was obtained from the National Poison Data System and the population data was obtained from the US Census Bureau to determine annual population estimates.
The investigators analyzed the data using chi-square tests and found that the rate of pediatric benzodiazepine exposure increased 54% between 2000-2015. They also found that the severity of medical outcomes and prevalence of co-ingestion of multiple drugs increased, particularly for individuals between 12-18 years old.
Approximately 50% of all reported exposures in 2015 were classified as intentional abuse, misuse, or attempted suicide, which reflects a change from data reported in prior years.
The most commonly identified pediatric benzodiazepines of exposures were alprazolam, clonazepam, and lorazepam.
In recent years, prescription drug abuse resulting in death have been an issue for people of all ages. While opioid analgesics are often pinpointed as the cause, there has been an increase in benzodiazepine exposures and overdoses.
The investigators suggest medical providers and caretakers be cognizant of the growing epidemic and take measures to avoid preventable harm to patients.
"While benzodiazepine overdose by itself is typically not life-threatening, the findings of this study show an increase in teens taking one or more additional substances, which increases the severity of the effects, including death or life-threatening symptoms that can affect future health," Calello said in a statement.
Approximately 70,000 children receive emergency care annually because of medication overdoses, with 12% of these visits requiring hospitalization. According to Calello, the increased availability of prescription medications is a likely cause of both adult and pediatric poisonings.
"Our study group found that the increasing rate of reported benzodiazepine exposures appear to reflect the increasing rate of benzodiazepine prescriptions that have been reported across the United States over the past decade," she said. "Medical providers should be aware of the increased prevalence of benzodiazepine exposures to help limit unnecessary prescribing. Parents and caregivers must be counseled on the proper use, storage and disposal of these high-risk medications."
According to a 2017 study, combining benzodiazepine with an antidepressant treatment regimen can create an addictive habit.
In the clinical trial, investigators paired benzodiazepine anxiolytic with an antidepressant for approximately 10% of patients starting medication treatment for major depression in a large US population study and found 12.3% of those patients continued the benzodiazepine for longer than 6 months and 2.4% continued it after stopping the antidepressant.
The study, “Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data,” was published online in Clinical Toxicology.